Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial.

About Veru Inc. Veru is a late clinical stage biopharmaceutical ... patients receiving semaglutide (Wegovy®). The trial met its prespecified primary endpoint with a statistically significant ...

Veru plans for end of Phase 2 meeting with FDA to discuss Phase 3 clinical program -- --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE ...

Veru is a late clinical-stage biopharmaceutical ... greater than or equal to 60 years of age receiving semaglutide, which is Wegovy, for weight for chronic weight management.

The treatment objective is for patients to have a healthier option for choosing to stop GLP-1s without the fear of fat regain,” said Mitchell Steiner, M.D., Chairman, President, and Chief Executive ...

The GLP-1 RA may be either WEGOVY (semaglutide ... to be Available for Phase 3 Clinical Studies and Commercialization Veru is currently developing a novel, patentable, modified release oral ...

MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical ... significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- - ...

Veru Inc. updates on its Phase 2b clinical trials ... patients receiving semaglutide (Wegovy Enobosarm + semaglutide treatment resulted in dose dependent greater loss of fat mass compared to ...

The GLP-1 RA may be either WEGOVY (semaglutide) and/or Zepbound® (tirzepatide ... is on Track to be Available for Phase 3 Clinical Studies and Commercialization Veru is currently developing a novel, ...

-- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- MIAMI ...

The GLP-1 RA may be either WEGOVY (semaglutide ... to be Available for Phase 3 Clinical Studies and Commercialization Veru is currently developing a novel, patentable, modified release oral ...